Brief: Kapruvia® (Difelikefalin) Recommended By England's NICE For Treatment Of Adults With Moderate-To-Severe CKD-Associated Pruritus
18/05/2023 07:03
May 18 (Reuters) - Cara Therapeutics Inc CARA.O :
* KAPRUVIA® (DIFELIKEFALIN) RECOMMENDED BY ENGLAND'S NICE
FOR
TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE CKD-ASSOCIATED
PRURITUS
Source text for Eikon: ID:nGNX4qdWzD
Further company coverage: CARA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tvardi Therapeutics
See all newsTvardi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tvardi Therapeutics Q2 net loss slightly lower estimates
Brief: Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:50 PM